Fluoroquinolones, including FACTIVE
, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart and lung transplants (See
FACTIVE, may exacerbate muscle weakness in persons with myasthenia gravis.┬á Avoid FACTIVE in patients with known history of myasthenia gravis (See
FACTIVE (gemifloxacin mesylate) is a synthetic broad-spectrum antibacterial agent for oral administration. Gemifloxacin, a compound related to the fluoroquinolone class of antibiotics, is available as the mesylate salt in the sesquihydrate form.
FACTIVE is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See
DOSAGE AND ADMINISTRATION
Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.
Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])*, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae.
*MDRSP: multi-drug resistant Streptococcus pneumoniae, includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 μg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of FACTIVE and other antibacterial drugs, FACTIVE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Published Studies Related to Factive (Gemifloxacin)
Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial. [2011.02]
OBJECTIVE: Acute exacerbation of chronic bronchitis (AECB) is a commonly encountered problem and those suspected to be due to bacterial infections require antibiotic therapy. This randomized, controlled trial was designed to evaluate the effectiveness and safety of gemifloxacin, a new fluoroquinolone, versus cefpodoxime, an oral third-generation cephalosporin, for the treatment of mild to moderately severe cases of AECB... CONCLUSION: The results of this randomized, single-blind trial demonstrated that a 7-day course of gemifloxacin is therapeutically comparable to cefpodoxime in terms of both clinical effectiveness and safety for the treatment of type II Anthonisen category AECB patients.
Bioequivalence evaluation of 320 mg gemifloxacin tablets in healthy volunteers. [2007.11]
This study was done to compare the bioavailability of a new tablet formulation of gemifloxacin (gemifloxacin 320 mg/tablet) with that of the reference product (factive 320 mg/tablet). The bioequivalence of a single dose (320 mg) was assessed for gemifloxacin included in the test and reference products by comparing the pharmacokinetic parameters derived from the plasma concentration-time profiles following administration to 24 healthy male volunteers in a balanced, 2-period, 2-sequence, 2-way crossover design.
Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. [2004.08]
CONTEXT: Community-acquired pneumonia (CAP) is common among adults and contributes considerably to morbidity and mortality. OBJECTIVE: To compare the safety and efficacy of gemifloxacin to high-dose amoxicillin/clavulanate for the treatment of CAP of suspected pneumococcal origin... CONCLUSION: Gemifloxacin 320 mg once daily for 7 days was found to be clinically, bacteriologically, and radiologically as effective as 10 days of amoxicillin/clavulanate 1 g/125 mg three times daily for the treatment of suspected pneumococcal CAP.
A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. [2004.08]
OBJECTIVE: To demonstrate that 5 days of treatment with a new fluoroquinolone, gemifloxacin, is at least as effective as 7 days of treatment with levofloxacin in adult patients with acute exacerbation of chronic bronchitis (AECB)... CONCLUSION: The clinical efficacy of gemifloxacin 320 mg once daily for 5 days in AECB was at least as good as levofloxacin 500 mg once daily for 7 days. Fewer withdrawals and superior clinical efficacy at long-term follow-up were also seen with gemifloxacin.
Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones. [2004.02]
The objective of this study was to determine serum bactericidal titers (SBT, the highest dilution of serum showing no growth) and the serum bactericidal activity (SBA, i.e. duration of SBT greater than 1:2) as well as the serum bactericidal rate of gemifloxacin and clarithromycin after single doses in healthy male volunteers against Streptococcus pneumoniae...
Clinical Trials Related to Factive (Gemifloxacin)
Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection [Recruiting]
New generations of fluoroquinolones, like levofloxacin and moxifloxacin, exhibit a
broad-spectrum activity against Gram-positive and Gram-negative bacteria, and have been
successfully introduced into the treatment of Helicobacter pylori infection. However, it was
suggested that resistance to fluoroquinolones has been increasing in the Korean population
and the resistance is most likely mediated through point mutation in gyrA. Gemifloxacin
(FACTIVE«) is an enhanced-affinity, broad-spectrum fluoroquinolone suitable for once-daily,
oral dosing. In vitro studies have shown that gemifloxacin displays potent activity against
Gram-positive organisms, whilst retaining good activity against Gram-negative organisms.
Gemifloxacin is the most potent member of the quinolone class against S. pneumoniae with
activities 16-64 times greater than those of ciprofloxacin and ofloxacin and 2-8 times
greater than those of moxifloxacin. Importantly, gemifloxacin displays potent in vitro
activity against strains of S. pneumoniae with known resistance to ╬▓-lactams, macrolides and
other members of the quinolone class. This potent activity is believed to be due to the
enhanced affinity of gemifloxacin for topoisomerase IV, the major fluoroquinolone target in
S. pneumoniae. Furthermore, gemifloxacin displays potent activity against H. influenzae and
M. catarrhalis and atypical organisms such as L. pneumophila, C. pneumoniae and M.
pneumoniae. It has proven particularly effective in respiratory and urinary tract infection.
Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg) [Completed]
This study seeks to compare the pharmacokinetic characteristics of Factive 200mg Intravenous
Formulation (Gemifloxacin 200mg) with those of Factive 320mg Tablet Formulation
(Gemifloxacin 320mg) and to explore possibility of clinical use of the IV formulation.
Efficacy of Combination Therapies for Gonorrhea Treatment [Completed]
The purpose of this study is to learn how to better treat gonorrhea infections. Gonorrhea is
a sexually transmitted disease (STD) that is usually cured with a single antibiotic.
However, some gonorrhea is not cured with a single antibiotic. The study will look at how
well treating gonorrhea with 2 antibiotics works. Participants will be assigned to 1 of 2
treatment groups each receiving a combination of 2 antibiotics. Sites in the United States
will recruit 500 male and female participants. Participants must be 15 to 60 years old, in
good health and identified in participating sexually transmitted disease clinics as having
uncomplicated cervical or urethral gonorrhea. Procedures include collection of current
symptoms, medical and sexual history, sexual orientation, vital signs, height, weight,
cervical/urethral cultures and clinical examinations. Volunteers will be involved for about
An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment [Completed]
The purpose of this study is to assess the association of retinal detachment (separation of
the retina [the innermost layer of the eyeball] from its connection at the back of the eye)
with exposure to oral ciprofloxacin or oral fluoroquinolones.
Reports of Suspected Factive (Gemifloxacin) Side Effects
Night Sweats (1),
Retinal Detachment (1),
Visual Acuity Reduced (1),
Vitreous Floaters (1),
Oedema (1), more >>
Page last updated: 2011-12-09